Cipla gets EIR from USFDA for Kurkumbh facility
- Country:
- India
Pharma major Cipla Monday said it has received establishment inspection report (EIR) from the US health regulator after inspection of Kurkumbh facility in Maharashtra. The Kurkumbh manufacturing facility was inspected by the United States Food and Drug Administration (USFDA) from March 11 to March 20, 2019, Cipla said in a BSE filing.
The company has received the EIR indicating closure of the inspection, it added. Shares of Cipla closed at Rs 553.70 per scrip on the BSE, up 0.75 per cent from its previous close.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
Advertisement
ALSO READ
Over 1.50 lakh new voters added in eight LS seats of Maharashtra
Good atmosphere in country, we are going to cross 400 seats in Lok Sabha polls: Amit Shah at Nanded rally in Maharashtra.
Make Modi PM again, his guarantee is to make India third largest economy in his third term: Amit Shah at rally in Maharashtra.
Congress stalled building of Ram temple at Ayodhya for 70 years: Union minister Amit Shah at rally in Maharashtra.
Ensuing Lok Sabha elections are about making Narendra Modi PM for third time: Amit Shah at rally in Maharashtra's Nanded.
Google News